Ventyx Biosciences, Inc. VTYX
We take great care to ensure that the data presented and summarized in this overview for Ventyx Biosciences, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VTYX
View all-
Deerfield Management Company, L.P. (Series C) New York, NY6.72MShares$15.1 Million0.27% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$10.7 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.46MShares$10 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$7.8 Million0.0% of portfolio
-
Farallon Capital Management LLC San Francisco, CA3.17MShares$7.13 Million0.03% of portfolio
-
Tang Capital Management LLC San Diego, CA3.1MShares$6.98 Million0.58% of portfolio
-
Octagon Capital Advisors LP New York, NY2.39MShares$5.38 Million1.26% of portfolio
-
Redmile Group, LLC San Francisco, CA2.11MShares$4.74 Million0.3% of portfolio
-
Sio Capital Management, LLC New York, NY1.97MShares$4.44 Million2.27% of portfolio
-
Goldman Sachs Group Inc New York, NY1.94MShares$4.35 Million0.0% of portfolio
Latest Institutional Activity in VTYX
Top Purchases
Top Sells
About VTYX
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Insider Transactions at VTYX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 19
2024
|
John Nuss CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
13,161
-2.64%
|
$26,322
$2.26 P/Share
|
|
Dec 17
2024
|
Raju Mohan CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
116,668
+4.84%
|
-
|
|
Dec 17
2024
|
John Nuss CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
34,930
+6.54%
|
-
|
|
Dec 10
2024
|
John Nuss CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
198,934
+15.69%
|
$0
$0.2 P/Share
|
|
Nov 25
2024
|
Raju Mohan CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
261,752
+10.74%
|
$523,504
$2.01 P/Share
|
|
Nov 22
2024
|
Raju Mohan CEO AND PRESIDENT |
BUY
Open market or private purchase
|
Direct |
238,248
+11.07%
|
$238,248
$1.83 P/Share
|
|
Jun 24
2024
|
Somu Subramaniam |
SELL
Other acquisition or disposition
|
Indirect |
641,327
-8.28%
|
-
|
|
Jun 24
2024
|
Nsv Partners Iii LP |
SELL
Other acquisition or disposition
|
Indirect |
641,327
-8.28%
|
-
|
|
Jun 10
2024
|
Raju Mohan CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
96,778
+5.46%
|
$0
$0.2 P/Share
|
|
Apr 12
2024
|
Somu Subramaniam |
SELL
Other acquisition or disposition
|
Indirect |
695,339
-8.24%
|
-
|
|
Apr 12
2024
|
Nsv Partners Iii LP |
SELL
Other acquisition or disposition
|
Indirect |
695,339
-8.24%
|
-
|
|
Apr 02
2024
|
Christopher W Krueger CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,651
-0.58%
|
$8,255
$5.4 P/Share
|
|
Apr 02
2024
|
Martin Auster CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,405
-5.47%
|
$7,025
$5.4 P/Share
|
|
Apr 02
2024
|
Raju Mohan CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
4,312
-0.27%
|
$21,560
$5.4 P/Share
|
|
Apr 02
2024
|
John Nuss CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
1,651
-0.62%
|
$8,255
$5.4 P/Share
|
|
Mar 28
2024
|
Christopher W Krueger CHIEF BUSINESS OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,531
+1.56%
|
-
|
|
Mar 28
2024
|
Raju Mohan CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
11,843
+0.74%
|
-
|
|
Mar 28
2024
|
Martin Auster CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,531
+14.98%
|
-
|
|
Mar 28
2024
|
John Nuss CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
4,531
+1.67%
|
-
|
|
Dec 20
2023
|
John Nuss CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
17,628
-6.3%
|
$35,256
$2.12 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 473K shares |
|---|---|
| Open market or private purchase | 500K shares |
| Open market or private sale | 22.2K shares |
|---|---|
| Other acquisition or disposition | 2.67M shares |